Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.

Nature communications - 29 Jan 2026

Jones Robin L, Groisberg Roman, Blay Jean-Yves, Colman Howard, De La Fuente Macarena, Roxburgh Patricia, Chao Mwe Mwe, Tian Hua, Duffaud Florence, Bahleda Rastislav, Van Tine Brian A

Abstract excerpt

Chondrosarcomas are rare cartilaginous neoplasms with limited treatment options. Isocitrate dehydrogenase 1/2 (mIDH1/2) mutations occur in 65% of chondrosarcomas. Here we report safety and efficacy of olutasidenib, an mIDH1 inhibitor, evaluated in patients with locally advanced or metastatic mIDH1 chondrosarcoma (Clinicaltrials.gov identifier: NCT03684811). The primary endpoint was objective response rate by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Neoplasms

Share to Chondrosarcoma

Share to Isocitrate Dehydrogenase

Share to Neoplasm Recurrence, Local

Share to Progression-Free Survival

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 41611702
DOI: 10.1038/s41467-026-68716-6
PMCID: PMC12963507

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.PMID 41611702Read ↗

Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcomaSemantic proximity Read ↗

High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation.Semantic proximity Read ↗

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcomaSemantic proximity Read ↗

Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.Semantic proximity Read ↗

Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?Semantic proximity Read ↗

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.Semantic proximity Read ↗

Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.Semantic proximity Read ↗

Clinical development of IDH1 inhibitors for cancer therapy.Semantic proximity Read ↗

The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.Semantic proximity Read ↗

Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1.Semantic proximity Read ↗

IDH1 Mutation Induces HIF-1α and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells.Semantic proximity Read ↗

Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic TargetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.